Although these reports highlighted a potentially influential role of BPA on ER activity in breast cancer, recent studies reveal BPA as an agonist for mutant androgen receptor (AR) activity in recurrent prostate cancer (Wetherill et al. 2002, 2005, 2006). Here, ESR1 is linked to prostate carcinoma.